Several new acyclonucleoside purine and 8‐azapurine analogs have been prepared from 2‐amino‐4,6‐dichloropyrimidine (1) and 3‐amino‐1,2‐propanediol (2a) and 4‐amino‐1‐butanol (2b), respectively, as the starting materials. The new target compounds are: 2‐amino‐6‐chloro‐9‐(2,3‐dihydroxypropyl)purine (6a), 2‐amino‐6‐chloro‐9‐(4‐hydroxybutyl)purine (6b), 2‐amino‐6‐chloro‐9‐(2,3‐dihydroxypropyl)‐8‐azapurine (7a), 2‐amino‐6‐chloro‐9‐(4‐hydroxybutyl)‐8‐azapurine (7b), 9‐(2,3‐dihydroxypropyl)‐8‐azaguanine (8a), 9‐(4‐hydroxybutyl)‐8‐azaguanine (8b), 9‐(2,3‐dihydroxypropyl)‐8‐azathioguanine (9a), and 9‐(4‐hydroxybutyl)‐8‐azathioguanine (9b). Also, the requisite intermediate pyrimidine derivatives, 2,5‐diamino‐4‐(2,3‐dihydroxypropylamino)‐6‐chloropyrimidine (5a) and 2,5‐diamino‐4‐(4‐hydroxybutylamino)‐6‐chloropyrimidine (5b) are novel.
No takes yet. Share an insight, caveat, or question.
Párkányi et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: